Preview Mode Links will not work in preview mode

This Week in Cardiology

Sep 3, 2021

EMPEROR-Preserved, the LOOP study, ablate-and-pace for AF, and salt substitute and stroke: John Mandrola, MD provides a first of two ESC reviews. To read a partial transcript or to comment, visit:

1 - HFpEF

- EMPEROR-Preserved: Empagliflozin Scores HFpEF Breakthrough

- Empagliflozin in Heart Failure with a Preserved Ejection Fraction

- Empagliflozin and Major Renal Outcomes in Heart Failure

- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

2 - AF Screening

- LOOP Trial Undercuts Value of Long-term Continuous ECG Screening for Atrial Fibrillation

- Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial

- Subclinical Atrial Fibrillation and the Risk of Stroke

3 - Ablate and Pace for AF and HF

- APAF-CRT: 'Ablate and Pace' Cuts Mortality in Narrow-QRS HF, Permanent AF

- A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS

- AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial

4 - Salt Substitute and Stroke

- Salt Substitute Shows Clear Reduction in Stroke, CV Events, and Death

- Effect of Salt Substitution on Cardiovascular Events and Death


- Incremental, Not Monumental, Win for Empagliflozin in Heart Failure With Preserved Ejection Fraction

- Empagliflozin in HFpEF: Putting EMPEROR-Preserved in Context

- Lessons on AF Screening From the LOOP Study

- Ablate-and-Pace Delivers a Huge Win for Those Sick With AF

- Will the Positive Findings From the SSaSS Trial on Salt Substitution Silence the Salt Skeptics?

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact